Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

Determined to "live as a healthy father," I administered my first injection of the lowest dose (2.5 mg) of the weight loss ...

Pre-diabetes offers a crucial chance to reset metabolism and prevent full diabetes. Longevity doctor Dr. Vassily Eliopoulos ...

and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is ...

LOUISVILLE, Ky. (WAVE) - Three sisters are questioning their father’s death, just days after he entered the care of a Southern Indiana nursing home. After just two days in the Waters of Clifty Falls ...

An AI tool showed noninferiority to senior endocrinology physicians in insulin titration for hospitalized patients with type 2 diabetes. About 99% of AI-based insulin recommendations were adopted by ...

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID ...

After launching a multi-campus phased rollout of the predictive insulin dosing software, Philadelphia-based Temple Health’s University Hospital has reduced hypoglycemia rates two- to threefold. The ...

– Acquisition extends Glooko’s diabetes digital health platform into hospitals, creating a comprehensive inpatient-to-outpatient diabetes management connected care solution – – Deal underscores Glooko ...